Obsidian Therapeutics enrols first patient in phase 1/2 Agni-01 study to evaluate Amsoki-cel in advanced melanoma: Cambridge, Massachusetts Saturday, August 8, 2026, 18:00 Hrs [IS ...
Emergent BioSolutions highlights for a cross-sector collaboration against biological threats in evolving global security environ: Gaithersburg, Maryland Saturday, August 8, 2026, ...
Kodiak Sciences completes enrollment in phase 3 PEAK trial of KSI-101 for macular edema secondary to inflammation: Palo Alto, California Saturday, August 8, 2026, 16:00 Hrs [IST] ...
Evotec and Odyssey Therapeutics ink AI-enabled R&D collaboration in autoimmune and inflammatory diseases: Hamburg, Germany Saturday, August 8, 2026, 15:00 Hrs [IST] Evotec SE, a l ...
Dispatch Bio begins patient dosing in phase 1 study of DISP-10, a novel investigational immunotherapy, in advanced gastrointestinal cancers: Philadelphia, San Francisco Saturday, ...
NHA achieves milestone with 25 crore OPD registrations through ABHA-based Scan and Register Service: Our Bureau, Mumbai Saturday, August 8, 2026, 13:45 Hrs [IST] In a significant ...
Union Minister of State (I/C) for Ayush, P Jadhav in a written reply in Lok Sabha stated that the Ministry of Ayush has launched several initiatives to promote the production, quality, research, ...
Govt strengthens affordable healthcare ecosystem through NHM, AB PM-JAY: Anupriya Patel: Our Bureau, Mumbai Saturday, August 8, 2026, 13:15 Hrs [IST] Union minister of state for h ...
Lucid Diagnostics secures commercial coverage policy spanning multiple health plans for its EsoGuard esophageal DNA test: New York Saturday, August 8, 2026, 13:00 Hrs [IST] Lucid ...
Priovant initiates patient enrolment in phase 3 study of brepocitinib in cutaneous sarcoidosis: Durham, North Carolina Saturday, August 8, 2026, 12:00 Hrs [IST] Priovant, a biotec ...
Mediar Therapeutics inks collaboration and option agreement with Ono Pharma to develop novel treatments for fibro-inflammatory diseases: Boston Saturday, August 8, 2026, 11:00 Hrs ...
Ractigen Therapeutics completes enrollment and first dosing in phase II trial of RAG-17 for SOD1-ALS
Ractigen Therapeutics completes enrollment and first dosing in phase II trial of RAG-17 for SOD1-ALS: Nantong, China Saturday, August 8, 2026, 10:00 Hrs [IST] Ractigen Therapeutic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results